Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice

Toxicology

Volumn 344-346, Issue , 2016, Pages 42-52

  Lorza Gil, Estela ^a   Salerno, Alessandro G ^a   Wanschel, Amarylis C B A ^a   Vettorazzi, Jean F ^a   Ferreira, Mônica S ^a   Rentz, Thiago ^a   Catharino, Rodrigo R ^a   Oliveira, Helena C F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cholesterol; Diabetes; Insulin secretion; LDL receptor; SNARE proteins; Statins

Indexed keywords

CASPASE 3; CHOLESTEROL; DIACYLGLYCEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHOLIPID; PRAVASTATIN; PROTEIN BAX; PROTEIN BCL 2; SNARE PROTEIN; SYNTAXIN 1A; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL DEATH; CELL ISOLATION; CONTROLLED STUDY; EX VIVO STUDY; EXOCYTOSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; INSULINEMIA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; EXOCYTOSIS; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PRAVASTATIN; RECEPTORS, LDL;

EID: 84958231632     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2015.12.007     Document Type: Article

References (47)

1. Acharya J.D., Ghaskadbi S.S. Islets and their antioxidant defense. Islets 2010, 2:225-235.
2. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2010, 87:98-107.
3. Bellia A., Rizza S., Lombardo M.F., Donadel G., Fabiano R., Andreadi K., Quon M.J., Sbraccia P., Federici M., Tesauro M., Cardillo C., Lauro D. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012, 223:197-203.
4. Bhunia A.K., Han H., Snowden A., Chatterjee S. Lactosylceramide stimulates Ras-GTP loading, kinases (MEK, Raf), p44 mitogen-activated protein kinase, and c-fos expression in human aortic smooth muscle cells. J. Biol. Chem. 1996, 271:10660-10666.
5. Bhunia A.K., Han H., Snowden A., Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J. Biol. Chem. 1997, 272:15642-15649.
6. Bonfleur M.L., Ribeiro R.A., Balbo S.L., Vanzela E.C., Carneiro E.M., de Oliveira H.C., Boschero A.C. Lower expression of PKAalpha impairs insulin secretion in islets isolated from low-density lipoprotein receptor (LDLR(-/-)) knockout mice. Metabolism 2011, 60:1158-1164.
7. Bonfleur M.L., Vanzela E.C., Ribeiro R.A., de Gabriel Dorighello G., de Franca Carvalho C.P., Collares-Buzato C.B., Carneiro E.M., Boschero A.C., de Oliveira H.C. Primary hypercholesterolaemia impairs glucose homeostasis and insulin secretion in low-density lipoprotein receptor knockout mice independently of high-fat diet and obesity. Biochim. Biophys. Acta 2010, 1801:183-190.
8. Boschero A.C., Delattre E. The mechanism of gentamicin-inhibited insulin release by isolated islets. Arch. Int. Pharmacodyn. Ther. 1985, 273:167-176.
9. Brault M., Ray J., Gomez Y.H., Mantzoros C.S., Daskalopoulou S.S. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014, 63:735-745.
10. Brunham L.R., Kruit J.K., Pape T.D., Timmins J.M., Reuwer A.Q., Vasanji Z., Marsh B.J., Rodrigues B., Johnson J.D., Parks J.S., Verchere C.B., Hayden M.R. Beta-cell ABCA1 influences insulin secretion: glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 2007, 13:340-347.
11. Bruns D., Jahn R. Molecular determinants of exocytosis. Pflugers Arch. 2002, 443:333-338.
12. Cederberg H., Stancakova A., Yaluri N., Modi S., Kuusisto J., Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015, 58:1109-1117.
13. Chamberlain L.H., Burgoyne R.D., Gould G.W. SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5619-5624.
14. Culver A.L., Ockene I.S., Balasubramanian R., Olendzki B.C., Sepavich D.M., Wactawski-Wende J., Manson J.E., Qiao Y., Liu S., Merriam P.A., Rahilly-Tierny C., Thomas F., Berger J.S., Ockene J.K., Curb J.D., Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 2012, 172:144-152.
15. Davignon J., Jacob R.F., Mason R.P. The antioxidant effects of statins. Coron. Artery Dis. 2004, 15:251-258.
16. Desai C.S., Martin S.S., Blumenthal R.S. Non-cardiovascular effects associated with statins. BMJ 2014, 349:g3743.
17. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:8931-8934.
18. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., Isles C., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J., Shepherd J., Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
19. Fryirs M., Barter P.J., Rye K.A. Cholesterol metabolism and pancreatic beta-cell function. Curr. Opin. Lipidol. 2009, 20:159-164.
20. Giniatullin A.R., Darios F., Shakirzyanova A., Davletov B., Giniatullin R. SNAP25 is a pre-synaptic target for the depressant action of reactive oxygen species on transmitter release. J. Neurochem. 2006, 98:1789-1797.
21. Gleason C.E., Gonzalez M., Harmon J.S., Robertson R.P. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line: HIT-T15. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E997-1002.
22. Goodarzi M.O., Li X., Krauss R.M., Rotter J.I., Chen Y.D. Relationship of sex to diabetes risk in statin trials. Diabetes Care 2013, 36:e100-101.
23. Halban P.A., Polonsky K.S., Bowden D.W., Hawkins M.A., Ling C., Mather K.J., Powers A.C., Rhodes C.J., Sussel L., Weir G.C. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J. Clin. Endocrinol. Metab. 2014, 99:1983-1992.
24. Hanson P.I., Heuser J.E., Jahn R. Neurotransmitter release-four years of SNARE complexes. Curr. Opin. Neurobiol. 1997, 7:310-315.
25. Hao M., Head W.S., Gunawardana S.C., Hasty A.H., Piston D.W. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007, 56:2328-2338.
26. Ishikawa M., Iwasaki Y., Yatoh S., Kato T., Kumadaki S., Inoue N., Yamamoto T., Matsuzaka T., Nakagawa Y., Yahagi N., Kobayashi K., Takahashi A., Yamada N., Shimano H. Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-transgenic mice: a new model for lipotoxicity. J. Lipid Res. 2008, 49:2524-2534.
27. Kashyap M.L., Tavintharan S., Kamanna V.S. Optimal therapy of low levels of high density lipoprotein-cholesterol. Am. J. Cardiovasc. Drugs 2003, 3:53-65.
28. La Guardia P.G., Alberici L.C., Ravagnani F.G., Catharino R.R., Vercesi A.E. Protection of rat skeletal muscle fibers by either l-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation. Front. Physiol. 2013, 4:103.
29. Martin S.F., Williams N., Chatterjee S. Lactosylceramide is required in apoptosis induced by N-Smase. Glycoconjugate J. 2006, 23:147-157.
30. Mora S., Glynn R.J., Hsia J., MacFadyen J.G., Genest J., Ridker P.M. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121:1069-1077.
31. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 2008, 29:351-366.
32. Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., DeMicco D.A., Barter P., Cannon C.P., Sabatine M.S., Braunwald E., Kastelein J.J., de Lemos J.A., Blazing M.A., Pedersen T.R., Tikkanen M.J., Sattar N., Ray K.K. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
33. Rafacho A., Marroquí L., Taboga S.R. Glucocorticoids in vivo induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. Endocrinology 2010, 151:85-95.
34. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., Group J.S. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359:2195-2207.
35. Rundek T., Naini A., Sacco R., Coates K., DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch. Neurol. 2004, 61:889-892.
36. Sattar N., Taskinen M.R. Statins are diabetogenic-myth or reality?. Atherosclerosis 2012, Suppl. 13:1-10.
37. Schachter M. Chemical: pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharm. 2005, 19:117-125.
38. Scott A.M., Atwater I., Rojas E. A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. Diabetologia 1981, 21:470-475.
39. Souza J.C., Vanzela E.C., Ribeiro R.A., Rezende L.F., de Oliveira C.A., Carneiro E.M., Oliveira H.C., Boschero A.C. Cholesterol reduction ameliorates glucose-induced calcium handling and insulin secretion in islets from low-density lipoprotein receptor knockout mice. Biochim. Biophys. Acta 2013, 1831:769-775.
40. Taverna E., Saba E., Rowe J., Francolini M., Clementi F., Rosa P. Role of lipid microdomains in P/Q-type calcium channel (Cav2: 1) clustering and function in presynaptic membranes. J. Biol. Chem. 2004, 279:5127-5134.
41. Taylor F., Huffman M.D., Macedo A.F., Moore T.H., Burke M., Davey Smith G., Ward K., Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 1:CD004816.
42. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995, 44:863-870.
43. Urayama S., Zou W., Brooks K., Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 2010, 24:613-620.
44. Velho J.A., Okanobo H., Degasperi G.R., Matsumoto M.Y., Alberici L.C., Cosso R.G., Oliveira H.C., Vercesi A.E. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology 2006, 219:124-132.
45. Vikman J., Jimenez-Feltstrom J., Nyman P., Thelin J., Eliasson L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J. 2009, 23:58-67.
46. 2+ channel is functionally coupled to the exocytotic machinery. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:248-253.
47. Zuniga-Hertz J.P., Rebelato E., Kassan A., Khalifa A.M., Ali S.S., Patel H.H., Abdulkader F. Distinct pathways of cholesterol biosynthesis impact on insulin secretion. J. Endocrinol. 2015, 224(January (1)):75-84. 10.1530/JOE-14-0348.